JP2011505414A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505414A5
JP2011505414A5 JP2010536523A JP2010536523A JP2011505414A5 JP 2011505414 A5 JP2011505414 A5 JP 2011505414A5 JP 2010536523 A JP2010536523 A JP 2010536523A JP 2010536523 A JP2010536523 A JP 2010536523A JP 2011505414 A5 JP2011505414 A5 JP 2011505414A5
Authority
JP
Japan
Prior art keywords
peptide
composition
subject
item
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010536523A
Other languages
English (en)
Japanese (ja)
Other versions
JP5501245B2 (ja
JP2011505414A (ja
Filing date
Publication date
Priority claimed from GBGB0723712.6A external-priority patent/GB0723712D0/en
Application filed filed Critical
Publication of JP2011505414A publication Critical patent/JP2011505414A/ja
Publication of JP2011505414A5 publication Critical patent/JP2011505414A5/ja
Application granted granted Critical
Publication of JP5501245B2 publication Critical patent/JP5501245B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010536523A 2007-12-04 2008-12-03 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 Expired - Fee Related JP5501245B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723712.6 2007-12-04
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
PCT/GB2008/003996 WO2009071886A1 (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014023217A Division JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Publications (3)

Publication Number Publication Date
JP2011505414A JP2011505414A (ja) 2011-02-24
JP2011505414A5 true JP2011505414A5 (enExample) 2012-10-25
JP5501245B2 JP5501245B2 (ja) 2014-05-21

Family

ID=38982965

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010536523A Expired - Fee Related JP5501245B2 (ja) 2007-12-04 2008-12-03 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用
JP2014023217A Expired - Fee Related JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014023217A Expired - Fee Related JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Country Status (25)

Country Link
US (1) US8445448B2 (enExample)
EP (1) EP2227488B3 (enExample)
JP (2) JP5501245B2 (enExample)
KR (1) KR101519840B1 (enExample)
CN (2) CN103709234B (enExample)
AU (1) AU2008332968B2 (enExample)
BR (1) BRPI0820143A2 (enExample)
CA (2) CA2707559C (enExample)
CY (1) CY1115168T1 (enExample)
DK (1) DK2227488T6 (enExample)
EA (1) EA019370B1 (enExample)
EC (1) ECSP10010327A (enExample)
ES (1) ES2458315T7 (enExample)
GB (1) GB0723712D0 (enExample)
HR (1) HRP20140344T4 (enExample)
IL (1) IL205780A (enExample)
MX (1) MX2010006084A (enExample)
MY (1) MY150995A (enExample)
NZ (1) NZ585217A (enExample)
PL (1) PL2227488T6 (enExample)
PT (1) PT2227488E (enExample)
SI (1) SI2227488T1 (enExample)
UA (1) UA101003C2 (enExample)
WO (1) WO2009071886A1 (enExample)
ZA (1) ZA201002997B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229489B1 (hu) 2000-08-21 2014-01-28 Apitope Technology Bristol Ltd Tolerogén peptidek
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
EP2300497B1 (en) * 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2765657A1 (en) * 2009-06-16 2010-12-23 Tokai University Anti-gram-negative bacteria agent
CN104926947A (zh) * 2010-10-27 2015-09-23 巴克斯特国际公司 用于免疫耐受性诱导和免疫诊断的fviii肽
BR112014017111A8 (pt) 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
BR112015010625B1 (pt) * 2012-11-12 2023-03-07 Apitope International Nv Peptídeos
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015615A1 (en) * 1989-06-20 1990-12-27 Scripps Clinic And Research Foundation The phospholipid binding domain of factor viii
IL130908A0 (en) * 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
HU229489B1 (hu) * 2000-08-21 2014-01-28 Apitope Technology Bristol Ltd Tolerogén peptidek
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
EP1729795B1 (en) * 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Similar Documents

Publication Publication Date Title
JP2011505414A5 (enExample)
Banik et al. Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy
Morató et al. Symptomatic and disease-modifying therapy pipeline for Alzheimer’s disease: Towards a personalized polypharmacology patient-centered approach
JP2012515778A5 (enExample)
US20170312334A1 (en) Methods and compositions for treating inflammatory disorders
Yang et al. Heart failure: advanced development in genetics and epigenetics
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
Stone et al. Genomics of human fibrotic diseases: disordered wound healing response
CN112679604A (zh) 用于肺癌(包括非小细胞肺癌和其他癌症)免疫治疗的新型肽和肽组合物
JP2017525336A5 (enExample)
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
JP2014533102A5 (enExample)
JP2017524348A5 (enExample)
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
JP2015504299A5 (enExample)
JP2009540852A5 (enExample)
JP2019500057A (ja) ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用
JP2012527440A5 (enExample)
Chattopadhyay et al. Preventing cholesterol-induced perk (protein kinase RNA-like endoplasmic reticulum kinase) signaling in smooth muscle cells blocks atherosclerotic plaque formation
Turcot et al. Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
JP2010526090A5 (enExample)
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
Hassan et al. Microglia-Mediated Phagocytosis in Alzheimer’s Disease: Mechanisms, Heterogeneity, and Therapeutic Insights